In their book “Pattern Breakers: How to find a breakthrough startup idea”, Mike Maples and Peter Ziebelman discuss inflection points, and how for startups to be successful they need to ride a significant inflection point, otherwise it will not reach the desired scale.
I am often asked “Why Now?” Well, because we are now at a time that combines several inflection points happening together, which makes building companies in Life Sciences especially exciting. Here are some notable inflection points that Life Science companies benefit from:
- Technology – new tools to read and write biology have been developed in the past decade, like DNA sequencing, gene editing, protein identification and manipulation have all created an unparalleled opportunity to research and develop in biology in larger scale, smaller prices and shorter time frame than ever before.For example, the cost and speed of gene sequencing (or reading DNA) have dropped dramatically. The Human Genome Project, completed in 2003, took over 10 years and cost nearly $3 billion. Today, sequencing an entire genome can be done in just a few hours for a few hundred dollars. This transformation was enabled by next-generation sequencing (NGS) technologies like Illumina and Oxford Nanopore, which use massively parallel sequencing methods to speed up the process. Entrepreneurs now have access to powerful data at lower costs, enabling them to create personalized medicine platforms, gene therapy ventures, and diagnostic tools.Gene editing (or writing DNA) with CRISPR-Cas9, discovered around 2012, is another example that has revolutionized genetic engineering by providing a more accessible and efficient way to edit DNA. With CRISPR, scientists can precisely cut and alter DNA sequences, enabling the development of gene therapies, genetically modified organisms, and synthetic biology products. This technology has spawned a wave of biotech startups focused on gene therapy, agriculture, and synthetic biology. Companies like CRISPR Therapeutics and Editas Medicine are pioneering new treatments for genetic disorders, while others are engineering microbes for industrial applications.
- AI – The AI revolution is amplifying advancements in biotechnology by transforming how we analyze and generate biological data, leading to breakthroughs in drug discovery, antibody design, and synthetic biology. AI enables faster analysis of large genomic datasets, helping to identify new biomarkers and personalize treatments. It also accelerates the design of new molecules, antibodies, and antibiotics, significantly reducing the time and cost of drug discovery. Startups like Insilico Medicine are using AI to streamline drug development, while others like AbCellera and the Israeli BiolojicDesign are leveraging AI to create novel antibodies and proteins for therapeutic use.
- Robotics – Automation technologies have made biological experimentation more scalable, accurate, and repeatable. Robotics and AI are now being used to automate lab workflows like pipetting, cell culture, and high-throughput screening. This reduces human error, increases the speed of experiments, and allows for higher scalability. Startups are using lab automation to accelerate drug discovery, streamline biological research, and even create fully automated labs. Companies like Benchling (cloud-based lab management) and Zymergen (automated synthetic biology, acquired by Gingko in 2022) are examples of how automation is enabling faster innovation cycles. These advancements have democratized access to complex biological tools, allowing smaller companies and even startups to compete in areas that were once reserved for large pharmaceutical or research institutions.
- Ecosystem – the ecosystem in life science innovation is rapidly developing. The recent decade has seen the establishment of pay-per-use lab spaces, efficient CROs, incubators and entrepreneurship programs that help scientists realize their technology into viable products and companies. Grants schemes that are targeting companies and research labs that seek to commercialize their research. The number of angels and VCs that appreciate the unique opportunity and fueling much needed funding to drive innovation.
There’s more work to be done. Most importantly, the ecosystem still has to develop in order to be able to support the very early stages of innovation. We are lacking support for scientists straight out of the lab, that are seeking to use their deep knowledge and expertise they developed over many years of research and apply them to bringing the much needed solutions to market.